Highlights from

American Academy of Dermatology

annual meeting 2018

San Diego 16-20 February 2018

Better gastrointestinal tolerability with biologics than the conventional therapy

In Switzerland, consenting patients with moderate-to-severe psoriasis enter the SDNTT (Swiss Dermatology Network for Targeted Therapies) Psoriasis Registry when they start systemic treatment. The purpose of adding the outpatient data to the non-interventional registry lies in obtaining long-term evidence for the efficacy and safety of these therapies in psoriasis and comparing adverse and serious adverse events between biological and non-biological drugs.

In the evaluation presented, 473 patients were included until December 2016: this corresponds to 264 patient years of biological and 272 years of non-biological systemic therapy [1]. Their mean age was 46.7 years, 65% were male and more than a third not only suffered from psoriasis but also from psoriatic arthritis.

Rates of serious adverse events and non-serious infection rates were not significantly different between the two treatment groups. The most reported non-serious adverse events were ineffectiveness of the drug with 15.8 % of patients treated with biologics and 16.6% in the non-biological group. Non-serious gastrointestinal side effects were significantly higher in the non-biological cohort compared to biological regimes (14.1 vs. 4.3/100 patient years; P≤0.05). All in all, serious adverse events were uncommon and without a different distribution among the two kinds of treatment.

  1. Maul, JT. et al. P5975, AAD Annual Meeting, February 16–20 2018.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.